Table 2.
Patient-based positivity rate of PSMA-11 PET/CT according to patients’ characteristics before PSMA-11 PET/CT
| Nb PSMA-11 PET/CTs | PSMA-11 negative | PSMA-11 equivocal | PSMA-11 positive | |
|---|---|---|---|---|
| Overall | 1084 | 22% | 9% | 68% |
| Gleason score (n = 1007) | χ2 p = 0.13 | |||
| < 7 | 179 | 28% | 8% | 63% |
| = 7 | 718 | 22% | 10% | 68% |
| > 7 | 199 | 20% | 6% | 73% |
| Initial therapy | χ2 p < 0.0001 | |||
| Prostatectomy (PX) | 877 | 25% | 10% | 64% |
| Other curative modality | 207 | 10% | 5% | 85% |
| Previous recurrence | χ2 p = 0.01 | |||
| No (1st recurrence) | 433 | 26% | 10% | 63% |
| Yes | 651 | 20% | 8% | 72% |
| serum PSA for PSMA-11 PET/CT (ng/mL) | χ2 p < 0.001 | |||
| < 0.2 | 17 | 41% | 18% | 41% |
| ≥ 0.2 < 0.5 | 166 | 45% | 13% | 42% |
| ≥ 0.5 < 1 | 173 | 27% | 10% | 63% |
| ≥ 1 < 2 | 257 | 23% | 11% | 67% |
| ≥ 2 | 471 | 12% | 7% | 81% |
| FCH PET/CT | χ2 p < 0.001 | |||
| Negative | +924 | 24% | 10% | 66% |
| Equivocal | 160 | 13% | 5% | 82% |